This resistance to CDK4/6 inhibitors caused by pRB loss of function would concern 6.8% and 7% of ACC patients, as estimated with the TCGA and the French cohorts of patients respectively [10,18]. This evidence concerns the gene CDK4 and adrenal cortex carcinoma.